利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.021 秒)

    Tetrahydro-isoquinolines
    3.
    发明授权
    Tetrahydro-isoquinolines 有权
    四氢异喹啉

    公开(公告)号：US08367699B2

    公开(公告)日：2013-02-05

    申请号：US12441266

    申请日：2007-09-14

    申请人： Lutz Weber ,  Vladimir Khazak ,  Gunther Ross ,  Cedric Kalinski ,  Christoph Burdack

    发明人： Lutz Weber ,  Vladimir Khazak ,  Gunther Ross ,  Cedric Kalinski ,  Christoph Burdack

    IPC分类号： C07D217/02 ,  A61K31/47

    CPC分类号： C07D217/26 ,  C07D401/04 ,  C07D409/04

    摘要： The present invention provides a compound selected from compounds of formula (A) as ligand binding to the HDM2 protein, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy and prevention. Compounds of formula (A) can be used as therapeutics for treating stroke, myocardial infarction, ischemia, multi-organ failure, spinal cord injury, Alzheimer's Disease, injury from ischemic events and heart valvular degenerative disease. Moreover, compounds of formula (A) can be used to decrease the side effects from cytotoxic cancer agents, radiation and to treat viral infections.

    摘要翻译： 本发明提供了选自式（A）化合物的化合物作为与HDM2蛋白结合的配体，诱导细胞凋亡和抑制增殖，并具有癌症治疗和预防的治疗效用。 式（A）化合物可用作治疗中风，心肌梗塞，局部缺血，多器官功能衰竭，脊髓损伤，阿尔茨海默病，缺血事件和心脏瓣膜退行性疾病的损伤的治疗剂。 此外，式（A）化合物可用于降低细胞毒性剂，辐射和治疗病毒感染的副作用。

    NOVEL TETRAHYDRO-ISOQUINOLINES
    4.
    发明申请
    NOVEL TETRAHYDRO-ISOQUINOLINES 有权
    新型四氢异喹啉

    公开(公告)号：US20090306130A1

    公开(公告)日：2009-12-10

    申请号：US12441266

    申请日：2007-09-14

    申请人： Lutz Weber ,  Vladimir Khazak ,  Gunther Ross ,  Cedric Kalinski ,  Christoph Burdack

    发明人： Lutz Weber ,  Vladimir Khazak ,  Gunther Ross ,  Cedric Kalinski ,  Christoph Burdack

    IPC分类号： A61K31/47 ,  C07D217/02 ,  A61P35/00

    CPC分类号： C07D217/26 ,  C07D401/04 ,  C07D409/04

    摘要： The present invention provides a compound selected from compounds of formula (A) as ligand binding to the HDM2 protein, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy and prevention. Compounds of formula (A) can be used as therapeutics for treating stroke, myocardial infarction, ischemia, multi-organ failure, spinal cord injury, Alzheimer's Disease, injury from ischemic events and heart valvular degenerative disease. Moreover, compounds of formula (A) can be used to decrease the side effects from cytotoxic cancer agents, radiation and to treat viral infections.

    摘要翻译： 本发明提供了选自式（A）化合物的化合物作为与HDM2蛋白结合的配体，诱导细胞凋亡和抑制增殖，并具有癌症治疗和预防的治疗效用。 式（A）化合物可用作治疗中风，心肌梗塞，局部缺血，多器官功能衰竭，脊髓损伤，阿尔茨海默病，缺血事件和心脏瓣膜退行性疾病的损伤的治疗剂。 此外，式（A）化合物可用于降低细胞毒性剂，辐射和治疗病毒感染的副作用。

    Tetrahydro-isoquinolin-1-ones for the treatment of cancer
    5.
    发明授权
    Tetrahydro-isoquinolin-1-ones for the treatment of cancer 有权
    用于治疗癌症的四氢异喹啉-1-酮

    公开(公告)号：US08163744B2

    公开(公告)日：2012-04-24

    申请号：US11909014

    申请日：2006-03-17

    申请人： Lutz Weber ,  Vladimir Khazak ,  Günther F Ross ,  Cotïc Kalinski ,  Christoph Burdack

    发明人： Lutz Weber ,  Vladimir Khazak ,  Günther F Ross ,  Cotïc Kalinski ,  Christoph Burdack

    IPC分类号： C07D413/02 ,  A61K31/47

    CPC分类号： C07D217/24

    摘要： The present invention provides a compound selected from compounds of formula I as ligand binding to the HDM2 protein, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy. Compounds of formula (I) can be used as therapeutics for treating stroke, myocardial infarction, ischemia, multi-organ failure, spinal cord injury, Alzheimer's Disease, injury from ischemic events, heart valvular degenerative disease Moreover, compounds of formula (I) can be used to decrease the side effects from cytotoxic cancer agents and to treat viral infections.

    摘要翻译： 本发明提供了选自式I化合物作为与HDM2蛋白结合的配体的化合物，诱导细胞凋亡和抑制增殖，并具有癌症治疗的治疗效用。 式（I）化合物可用作治疗中风，心肌梗塞，局部缺血，多器官功能衰竭，脊髓损伤，阿尔茨海默氏病，缺血事件的损伤，心脏瓣膜变性疾病的治疗剂。此外，式（I）化合物可 用于减少细胞毒性剂的副作用并治疗病毒感染。